General InformationEisai is a Tokyo-based public pharmaceutical company founded in 1957 with over 10,000 employees that focuses on drug discovery and development across oncology, neurology, and immunology sectors.
Funding & FinancialsAs a public company listed on the Tokyo Stock Exchange since 1967, Eisai has access to capital markets rather than traditional venture funding rounds.
Leadership & TeamHaruo Naito is the founder; current leadership includes CEO and executive officers managing global operations across R&D, commercial, and business development functions.
Recent ActivityEisai continues advancing multiple oncology and neurology pipeline candidates, with recent focus on Alzheimer's disease treatments including collaboration agreements with major global partners for market expansion.